The risk of major adverse cardiac events (MACEs), MI, stroke, CHF, and coronary revascularization in RA patients treated with TCZ did not exceed that in patients treated with other biologics (TNF-α inhibitors, abatacept, and rituximab). Here, TNF is linked to congestive heart failure.